Baldwin Investment Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $509K | Buy |
8,400
+25
| +0.3% | +$1.46K | 0.06% | 154 |
|
|
2025
Q4 | $452K | Buy |
8,375
+6
| +0.1% | +$289 | 0.05% | 161 |
|
|
2025
Q3 | $377K | Sell |
8,369
-5,770
| -41% | -$269K | 0.04% | 170 |
|
|
2025
Q2 | $654K | Buy |
14,139
+7
| +0% | +$344 | 0.08% | 136 |
|
|
2025
Q1 | $862K | Buy |
14,132
+4,733
| +50% | +$276K | 0.1% | 114 |
|
|
2024
Q4 | $532K | Sell |
9,399
-1,750
| -16% | -$97.8K | 0.07% | 147 |
|
|
2024
Q3 | $577K | Sell |
11,149
-700
| -6% | -$32.8K | 0.07% | 146 |
|
|
2024
Q2 | $492K | Sell |
11,849
-5,630
| -32% | -$252K | 0.07% | 147 |
|
|
2024
Q1 | $948K | Sell |
17,479
-650
| -4% | -$33.1K | 0.13% | 110 |
|
|
2023
Q4 | $930K | Sell |
18,129
-15,185
| -46% | -$797K | 0.15% | 100 |
|
|
2023
Q3 | $1.93M | Sell |
33,314
-21,021
| -39% | -$1.29M | 0.32% | 50 |
|
|
2023
Q2 | $3.47M | Sell |
54,335
-7,082
| -12% | -$475K | 0.57% | 25 |
|
|
2023
Q1 | $4.26M | Sell |
61,417
-1,971
| -3% | -$139K | 0.76% | 16 |
|
|
2022
Q4 | $4.56M | Sell |
63,388
-1,125
| -2% | -$84.8K | 0.82% | 14 |
|
|
2022
Q3 | $4.59K | Sell |
64,513
-5,301
| -8% | -$385K | 0.93% | 9 |
|
|
2022
Q2 | $5.38K | Sell |
69,814
-2,822
| -4% | -$215K | 1.02% | 6 |
|
|
2022
Q1 | $5.3K | Buy |
72,636
+1,640
| +2% | +$110K | 0.8% | 13 |
|
|
2021
Q4 | $4.43K | Sell |
70,996
-4,866
| -6% | -$285K | 0.69% | 25 |
|
|
2021
Q3 | $4.49M | Buy |
75,862
+791
| +1% | +$52.1K | 0.78% | 16 |
|
|
2021
Q2 | $5.02M | Buy |
75,071
+2,848
| +4% | +$186K | 0.85% | 10 |
|
|
2021
Q1 | $4.56M | Buy |
72,223
+4,676
| +7% | +$291K | 0.83% | 12 |
|
|
2020
Q4 | $4.19M | Buy |
67,547
+10,962
| +19% | +$674K | 0.83% | 14 |
|
|
2020
Q3 | $3.41M | Buy |
56,585
+17,199
| +44% | +$1.04M | 0.8% | 18 |
|
|
2020
Q2 | $2.32M | Buy |
39,386
+766
| +2% | +$45.8K | 0.73% | 24 |
|
|
2020
Q1 | $2.15M | Buy |
38,620
+5,975
| +18% | +$365K | 0.74% | 17 |
|
|
2019
Q4 | $2.1M | Buy |
32,645
+21,720
| +199% | +$1.24M | 0.56% | 23 |
|
|
2019
Q3 | $554K | Buy |
10,925
+691
| +7% | +$32.5K | 0.16% | 95 |
|
|
2019
Q2 | $464K | Buy |
+10,234
| New | +$477K | 0.13% | 109 |
|
|
2019
Q1 | – | Sell |
-4,109
| Closed | -$214K | – | 167 |
|
|
2018
Q4 | $214K | Hold |
4,109
| – | – | 0.07% | 148 |
|
|
2018
Q3 | $255K | Sell |
4,109
-400
| -9% | -$23.7K | 0.07% | 148 |
|
|
2018
Q2 | $250K | Buy |
+4,509
| New | +$244K | 0.08% | 152 |
|
Other funds holding BMY
VCM
VPM
Baldwin Investment Management's BMY Position: Q1 2026 in Review
Baldwin Investment Management increased its Bristol-Myers Squibb (BMY) stake by 0.3% in Q1 2026, buying an estimated $1.46K and bringing the position to 8,400 shares worth $509K. The position accounts for 0.06% of the portfolio, ranked #154.
Baldwin Investment Management first reported a position in BMY in Q2 2018 and has held it in 31 quarters since. The position peaked at $5.02M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Baldwin Investment Management held 8,400 shares of Bristol-Myers Squibb worth $509K as of Q1 2026.
- Baldwin Investment Management bought 25 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.46K.
- Bristol-Myers Squibb made up 0.06% of Baldwin Investment Management's portfolio in Q1 2026, its #154 holding.
- Baldwin Investment Management first reported a position in Bristol-Myers Squibb in Q2 2018 and has held it in 31 quarters since.
- Baldwin Investment Management's Bristol-Myers Squibb position peaked at $5.02M in Q2 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Baldwin Investment Management's 13F filing for Q1 2026, filed 12 May 2026.